Online inquiry

IVTScrip™ mRNA-Anti-CD274, MPDL3280A(Cap 1, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ12242MR)

This product GTTS-WQ12242MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD274 gene. The antibody can be applied in Solid tumors, Renal cell carcinoma (RCC) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001267706.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 29126
UniProt ID Q9NZQ7
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD274, MPDL3280A(Cap 1, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ12242MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ9699MR IVTScrip™ mRNA-Anti-KLRK1, JNJ-64304500(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA JNJ-64304500
GTTS-WQ885MR IVTScrip™ mRNA-Anti-PDCD1, ABBV-181(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ABBV-181
GTTS-WQ8985MR IVTScrip™ mRNA-Anti-IL22, ILV-094(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ILV-094
GTTS-WQ9078MR IVTScrip™ mRNA-Anti-IGF1R, IMC-A12(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA IMC-A12
GTTS-WQ3215MR IVTScrip™ mRNA-Anti-CD70, ARGX-110(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA ARGX-110
GTTS-WQ2862MR IVTScrip™ mRNA-Anti-ICOS, AMG-570(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA AMG-570
GTTS-WQ14638MR IVTScrip™ mRNA-Anti-DLL3, SC0001-SCX(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA SC0001-SCX
GTTS-WQ3995MR IVTScrip™ mRNA-Anti-PDCD1, BGB-A317(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BGB-A317
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW